on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Secures Exclusive Rights for Cold Plasma Therapy with CORIUS Group
Viromed Medical AG announced a significant agreement with CORIUS Group for the exclusive use of its cold plasma therapy, Plasma Care®. This partnership aims to provide the innovative treatment exclusively to CORIUS Group's database of 1.25 million patients across Europe, starting from 2025.
The deal is expected to bolster Viromed's financial performance significantly, with an anticipated additional earnings contribution ranging from EUR 0.28 to EUR 0.34 per share. This development marks a strategic step for Viromed in expanding its presence and utility in dermatological and phlebological care by integrating Plasma Care® as a principal treatment option within one of Europe's largest medical practice networks.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news